Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro

Authors: Karen Anbro Gammeltoft, Yuyong Zhou, Carlos R. Duarte Hernandez, Andrea Galli, Anna Offersgaard, Rui Costa, Long V. Pham, Ulrik Fahnøe, Shan Feng, Troels K. H. Scheel, Santseharay Ramírez, Jens Bukh, Judith M. Gottwein - Antimicrobial Agents and Chemotherapy 2021 cited by 46

Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PIs) against SARS-CoV-2 and their interactions with remdesivir, the only direct-acting antiviral approved for COVID-19 treatment.